title: Reply to Y. Sunakawa et al and P. Mroczkowski et al.
authors.affiliation: Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
authors.forename: Le-Chi
authors.initials: LC
authors.lastname: Ye
authors.forename: Yun-Shi
authors.initials: YS
authors.lastname: Zhong
authors.forename: Qi
authors.initials: Q
authors.lastname: Lin
authors.forename: Jianmin
authors.initials: J
authors.lastname: Xu
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D006498:Hepatectomy / Q000379:methods; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab